Back to Search
KENNETH HORWITZ, M.D.
M.D.
Internal Medicine Physician
NPI: 1225138829Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G59007(CA)
Research & Publications (20)
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
PMID 18391223·Proc Natl Acad Sci U S A·2008
7-preclinical
The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.
PMID 18845670·Mol Endocrinol·2008
6-review
Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis.
PMID 18647813·J Clin Endocrinol Metab·2008
8-other
ALU repeats in promoters are position-dependent co-response elements (coRE) that enhance or repress transcription by dimeric and monomeric progesterone receptors.
PMID 19372234·Mol Endocrinol·2009
8-other
Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation.
PMID 19211567·J Biol Chem·2009
8-other
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
PMID 18487993·Mod Pathol·2008
4-observational
Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.
PMID 18338247·Breast Cancer Res Treat·2008
7-preclinical
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.
PMID 18327671·Breast Cancer Res Treat·2008
3-trial
Progesterone receptor action: translating studies in breast cancer models to clinical insights.
PMID 18637487·Adv Exp Med Biol·2008
6-review
Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases.
PMID 17932773·Clin Exp Metastasis·2008
4-observational
Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.
PMID 17975003·Cancer Res·2007
7-preclinical
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
PMID 16982776·Cancer Res·2006
7-preclinical
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
PMID 17043687·Br J Cancer·2006
8-other
Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium.
PMID 16912208·Cancer Res·2006
7-preclinical
Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone.
PMID 17053081·Proc Natl Acad Sci U S A·2006
8-other
GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway.
PMID 16478993·Mol Cell Biol·2006
7-preclinical
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.
PMID 16585218·Cancer Res·2006
7-preclinical
Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.
PMID 16762974·Mol Endocrinol·2006
8-other
Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture.
PMID 16239301·Endocrinology·2006
4-observational
Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
PMID 16266999·Cancer Res·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1211 W LA PALMA AVE, #207
ANAHEIM, CA 92801 - Phone
- (714) 772-8282
Quick Facts
- NPI
- 1225138829
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile